Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2019, 28(4):174-177

The potential effect of LHRH angonists on myocardial angiogenesis

Valášková Z1, Hulín I1, El Hassoun O2, Polák Š2, Mladosievičová B1
1 Oddelenia klinickej patofyziológie LF UK v Bratislave
2 Ústav histológie a embryológie LF UK v Bratislave, Slovenská republika

Luteinizing hormone-releasing hormone agonists have anti-angiogenic effects in tumor tissue. They are also likely to be associated with an increased cardiovascular risk in patients with prostate carcinoma, especially in those with preexisting cardiac and vascular disease. Studies aiming to elucidate the mechanisms by which androgen deprivation therapy causes cardiovascular effects are rare. We believe that luteinizing hormone-releasing hormone agonists can impair myocardial angiogenesis. In patients with myocardial disease can deepen hypoxia, significantly worsen the condition of the myocardium, and therefore increase the risk of heart failure. Careful assessment of the myocardial status and consequent timing and typing of cancer therapy could minimalize the adverse effects of treatment. Ideally through close cooperation between cardiologists and oncologists.

Keywords: angiogenesis; cardiovascular risk; follicle stimulating hormone; LHRH agonist; testosterone

Published: April 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Valášková Z, Hulín I, El Hassoun O, Polák Š, Mladosievičová B. The potential effect of LHRH angonists on myocardial angiogenesis. Cardiology Letters. 2019;28(4-5):174-177.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014;65:565-573. Go to original source...
    2. Poljak Z, Hulin I, Maruscakova L, et al. Androgen deprivation therapy and cardiovascular complications. Bratisl Med J 2016;117:557-561. Go to original source...
    3. Poljak Z, Hulin I, Maruscakova L, et al. Are GnRH and FSH potentially damaging factors in the cardiovascular system? Pharmazie 2018;73:187-190. Go to original source...
    4. Elagizi A, Köhler TS, Lavie CJ. Testosterone and cardiovascular health. Mayo Clin Proc 2018;93:83-100. Go to original source...
    5. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-4456. Go to original source...
    6. Asai A, Miyata Y, Matsuo T, et al. Changes in lymphangiogenesis and vascular endothelial growth factor expression by neoadjuvant hormonal therapy in prostate cancer patients. Prostate 2017;77:255-262. Go to original source...
    7. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal 2006;8:1907-1939. Go to original source...
    8. Bodi V, Monmeneu JV, Ortiz-Perez JT, et al. Prediction of Reverse Remodeling at Cardiac MR Imaging Soon after First STSegment-Elevation Myocardial Infarction: Results of a Large Prospective Registry. Radiology 2016;278:54-63. Go to original source...
    9. Niccoli G, Scalone G, Lerman A, et al. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J 2016;37:1024-1033. Go to original source...
    10. Cochain C, Channon KM, Silvestre JS. Angiogenesis in the infarcted myocardium. Antioxid Redox Signal 2013;18:11001113. Go to original source...
    11. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967-974. Go to original source...
    12. Hueso L, Rios-Navarro C, Ruiz-Sauri A, et al. Dynamics and implications of circulating anti-angiogenic VEGF-A165b isoform in patients with ST-elevation myocardial infarction. Sci Rep 2017;7:9962. Go to original source...
    13. Albrecht-Schgoer K, Schgoer W, Holfeld J, et al. The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells. Circulation 2012;126:2491-2501. Go to original source...
    14. Meresman GF, Bilotas MA, Lombardi E, et al. Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod 2003;18:17671771. Go to original source...
    15. Wang XF, Qu XQ, Zhang TT, et al. Testosterone suppresses ventricular remodeling and improves left ventricular function in rats following myocardial infarction. Exp Ther Med 2015;9:1283-1291. Go to original source...
    16. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531-1538. Go to original source...
    17. Lepor H, Shore ND. LHRH Agonists for the treatment of prostate cancer: 2012. Rev Urol 2012;14:1-12.
    18. Czaja E, Wieciech-Rojkiewicz I, Knapczyk-Stwora K, et al. The impact of antiandrogen flutamide on the hypoxia inducible factor 1a and vascular endothelial growth factor A gene and protein expression in the pig placenta during late pregnancy. Folia Histochem Cytobiol 2017;55:159-167. Go to original source...
    19. Woodward WA, Wachsberger P, Burd R, et al. Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. Prostate Cancer Prostatic Dis 2005;8:127-132. Go to original source...
    20. Foresta C, Caretta N, Lana A, et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab 2006;91:4599-4602. Go to original source...
    21. Stilley JA, Guan R, Duffy DM, et al. Signaling through FSH receptors on human umbilical vein endothelial cells promotes angiogenesis. J Clin Endocrinol Metab 2014;99:E813-20. Go to original source...
    22. Huang Y, Hua K, Zhou X, et al. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res 2008;18:780-791. Go to original source...
    23. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008;266:37-52. Go to original source...
    24. Yang M, Li B, Liu J, et al. Protection effect of survivin protein overexpression on acute myocardial infarction in rats. Int J Clin Exp Med 2015;8:12995-3000.
    25. Margel D, Peer A, Ber Y, et al. Early cardiovascular morbidity in a pilot prospective randomized trial comparing LHRH agonist and antagonist among patients with advanced prostate cancer. J Urol 2017;197:suppl e768. Go to original source...

    Return to the content